2 results
Approved WMOCompleted
Primary objectives-Determine efficacy, defined as PFS and OS at 2 years of risk-adaptive DA-EPOCH-R in newly diagnosed Burkitt lymphoma patients 18-75 years.-Determine feasibility, defined as > 60% of cycles of the DA-EPOCH-R scheme on an out…
Approved WMOCompleted
To study whether a novel plaster (Rapydan) is more successfull in diminishing pain/ discomfort than the usual plaster (EMLA).